What role does MTWA testing play in MADIT II and SCD-Heft patients?
In both MADIT II and SCD-Heft patient groups are now eligible for ICD therapy as a primary prevention treatment and are ideal candidates to be risk stratified by MTWA testing prior to referral to electrophysiologist. Patients in these groups who have a normal MTWA test are not likely to experience a sudden cardiac event for 1-2 years and therefore not likely to benefit from ICD therapy.
